CRISPR screen identifies autophagy inhibition (GNS561) as a PARP inhibitor (AZD5305) combination strategy in small cell lung cancer
Tony Yu, Ranya Barayan, Lifang Song, Vidhyasagar Venkatasubramanian, Janvi Tamakuwala, Sree N Nair, Vivek Philip, Benjamin H Lok · 2026
Read CRISPR screen identifies autophagy inhibition (GNS561) as a PARP inhibitor (AZD5305) combination strategy in small cell lung cancer by Tony Yu, Ranya Barayan, Lifang Song, Vidhyasagar Venkatasubramanian, Janvi Tamakuwala, Sree N Nair, Vivek Philip, Benjamin H Lok (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13551694.txt.
Description
Tony Yu, leading seven colleagues, published a 2026 study hunting for drug combinations that make small cell lung cancer respond to PARP inhibitors, a class that blocks DNA repair. Responses vary, so the team ran a genome-wide CRISPR screen in two cancer cell lines under the PARP inhibitor olaparib, watching which gene losses made cells die. Follow-up tests used gene knockdown and cell viability assays.
Losing regulators that restrain the mTOR pathway sensitized cells, pointing toward autophagy, the cell's recycling system, as a partner target. Combining a newer PARP inhibitor, AZD5305, with an autophagy inhibitor, GNS561, acted synergistically in cell lines and worked in mouse tumors grown from those lines. The authors propose the pairing for further development.
Catalog record
| CREATOR | Tony Yu, Ranya Barayan, Lifang Song, Vidhyasagar Venkatasubramanian, Janvi Tamakuwala, Sree N Nair, Vivek Philip, Benjamin H Lok |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44705 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |